Michael Heinrich

Professor

  • 34587 Citations
  • 82 h-Index
1985 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Michael Heinrich is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Heinrich, M. C., Jones, R. L., von Mehren, M., Schöffski, P., Serrano, C., Kang, Y. K., Cassier, P. A., Mir, O., Eskens, F., Tap, W. D., Rutkowski, P., Chawla, S. P., Trent, J., Tugnait, M., Evans, E. K., Lauz, T., Zhou, T., Roche, M., Wolf, B. B., Bauer, S. & 1 others, George, S., Jul 2020, In : The Lancet Oncology. 21, 7, p. 935-946 12 p.

Research output: Contribution to journalArticle

  • 4 Scopus citations

    Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study

    Von Mehren, M., George, S., Heinrich, M. C., Schuetze, S. M., Yap, J. T., Yu, J. Q., Abbott, A., Litwin, S., Crowley, J., Belinsky, M., Janeway, K. A., Hornick, J. L., Flieder, D. B., Chugh, R., Rink, L. & Van Den Abbeele, A. D., Apr 15 2020, In : Clinical Cancer Research. 26, 8, p. 1837-1845 9 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

    Blay, J. Y., Serrano, C., Heinrich, M. C., Zalcberg, J., Bauer, S., Gelderblom, H., Schöffski, P., Jones, R. L., Attia, S., D'Amato, G., Chi, P., Reichardt, P., Meade, J., Shi, K., Ruiz-Soto, R., George, S. & von Mehren, M., Jul 2020, In : The Lancet Oncology. 21, 7, p. 923-934 12 p.

    Research output: Contribution to journalArticle

  • 7 Scopus citations

    Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: A phase i study of ripretinib

    Janku, F., Abdul Razak, A. R., Chi, P., Heinrich, M. C., Von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Somaiah, N., Hu, S., Rosen, O., Su, Y., Ruiz-Soto, R., Gordon, M. & George, S., Oct 1 2020, In : Journal of Clinical Oncology. 38, 28, p. 3294-3303 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

    Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations